Walvax Biotechnology
Walvax Biotechnology Co, Ltd, a biological pharmaceutical company.
Launch date
Employees
Market cap
$2.2b
Enterprise valuation
$1.8b (Public information from Sep 2024)
Share price
CNY9.93 300142.SZ
Kunming China (HQ)
Financials
Estimates*
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 2.9b | 3.5b | 5.1b | 4.1b | 3.5b | 4.4b | 4.5b |
| % growth | 162 % | 18 % | 47 % | (19 %) | (15 %) | 25 % | 2 % |
| EBITDA | 1.2b | 1.1b | 1.6b | 1.4b | 1.2b | 1.5b | 1.7b |
| % EBITDA margin | 40 % | 32 % | 32 % | 34 % | 34 % | 34 % | 38 % |
| Profit | 1.0b | 428m | 729m | 419m | 473m | 895m | 940m |
| % profit margin | 34 % | 12 % | 14 % | 10 % | 14 % | 21 % | 21 % |
| EV / revenue | 20.3x | 24.9x | 12.0x | 8.3x | 3.8x | 2.9x | 2.7x |
| EV / EBITDA | 50.5x | 77.7x | 36.9x | 24.1x | 10.9x | 8.5x | 7.1x |
| R&D budget | 176m | 621m | 933m | 776m | - | - | - |
| R&D % of revenue | 6 % | 18 % | 18 % | 19 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| N/A | $72.8m | Post IPO Equity | |
| Total Funding | - | ||
Related Content
Recent News about Walvax Biotechnology
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
exited